One hundred years ago, Ramón y Cajal, considered by many as the founder of modern
neuroscience, stated that neurons of the adult central nervous system (CNS) are incapable …

Since no approved therapies to restore mobility and sensation following spinal cord injury
(SCI) currently exist, a better understanding of the cellular and molecular mechanisms …

Chondroitin sulfate proteoglycans (CSPGs) inhibit repair following spinal cord injury. Here
we use mammalian-compatible engineered chondroitinase ABC (ChABC) delivered via …

Highlights•Regeneration and sprouting are two forms of injury-induced axonal
growth.•Myelin inhibitors modulate axonal sprouting after CNS injury.•Regeneration elicited …

Inhibitory extracellular matrices form around mature neurons as perineuronal nets
containing chondroitin sulfate proteoglycans that limit axonal sprouting after CNS injury. The …

Chondroitinase ABC is a promising preclinical therapy that promotes functional
neuroplasticity after CNS injury by degrading extracellular matrix inhibitors. Efficient delivery …

Axonal regeneration and functional recovery are poor after spinal cord injury (SCI), typified
by the formation of an injury scar. While this scar was traditionally believed to be primarily …

Brain and spinal cord injury can result in permanent cognitive, motor, sensory and
autonomic deficits. The central nervous system (CNS) has a poor intrinsic capacity for …

Many studies, using pre-clinical models of SCI, have demonstrated the efficacy of
chondroitinase ABC as a treatment for spinal cord injury and this has been confirmed in …

Rats have been the primary model to study the process and underlying mechanisms of
recovery after spinal cord injury. Two weeks after a severe spinal cord contusion, rats can …